

## Risk Profile

SRRI						
1	2	3	4	5	6	7

## Fund Profile

The Fund is a UCITS4 Swiss long-only equity fund. The Fund's objective is to achieve an attractive long term capital growth with an optimal risk taking consideration. It is intended to maintain a high equity ratio in a positive stock market environment for equities. The equity ratio is to be reduced when the investment manager deems necessary a temporary reduction of exposures. The Fund will invest on Swiss corporates listed in regulated markets and equity indices.

## Fund Facts

Fund Focus	Equity
Fund Geographical Focus	Switzerland
Fund of Funds	Yes
Investment Manager	Copernicus Wealth Management SA
Investment manager since	2021-07-23
Location	Lugano
Fund domicile	Luxembourg
UCITS	Yes
Fund currency	CHF
Close of financial year	31st December
Inception date	2021-07-23
Countries of distribution	Italy, Luxembourg, Switzerland
Management Company	MultiConcept Fund Management SA
Depository	Credit Suisse (Luxembourg) SA
Administrator	Credit Suisse Fund Services (Luxembourg) SA
Auditor	PwC Luxembourg SC
Dealing Frequency	Daily
Subscriptions	0 days notice
Redemptions	1 day notice
Last NAV	85.9
Total Assets (Millions)	47.49

## Performance Chart




Performance	3 Months	6 Months	YTD	1 Year	Since Inception
	1.2%	9.2%	9.0%	-8.0%	-14.1%


## Monthly Performance Net of Fees (last 3 years)

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Yearly
2023	7.7%	-0.1%	0.3%	1.0%									9.0%
2022	-7.4%	-2.7%	1.8%	-2.4%	-4.1%	-7.2%	2.8%	-4.8%	-7.4%	4.4%	3.5%	-3.2%	-24.6%
2021							0.4%	2.9%	-3.6%	3.1%	-1.7%	3.5%	4.5%

## Exposures



## Historical Sector



## Fund Statistics

	Since Inception	1 Year
Annualized Volatility (%)	15.3	14.7
Annualized Downside Volatility (%)	10.8	10.0
Max Drawdown (%)	30.2	20.6
Sharpe Ratio	-0.5	-0.4

## Top holdings

Instrument	% of Assets
Roche	8.3
Novartis	7.2
Compagnie Financière Richemont	6.8
Nestlé	6.5
Holcim	6.2

## Monthly Commentary

The Swiss equity market posted a positive performance in April, positively affected by the big defensive names, which benefitted from the rotation away from cyclical names. The Fund 's performance was also positive with a +1.0% monthly gain, which brought the annual increase up to +9.0%. The Swiss Manufacturing PMI stood at 45.3 in April, well below the growth threshold of 50pts, posting the fourth consecutive monthly contraction, negatively hit by the downward trend posted by the order backlog and the related drop in the quantity of purchases. As for inflation, the April figure showed positive signals, with the headline figure which came in at 2.6%, almost 1 percentage point down compared to the peak of August. Looking at the Fund composition, we continue to maintain a defensive portfolio structure with a meaningful exposure toward the Healthcare and the Consumer Staples sectors as we believe the related earnings may be less impacted by a possible macro-economic slowdown. Roche and Novartis are currently our top holdings, followed by Richemont and Nestlé. Novartis is among our top picks as we believe that consensus is underestimating the potential of Novartis's breast cancer drug Kisqali, and the consequences of the NATALEE study which has delivered in March success at an interim analysis.

## Fund classes

Class	Class Type	CCY	Launch Date	Min. Inv.	ISIN	Bloomberg Ticker	Management Fee	Performance Fee
I CHF	Institutional - Accumulation	CHF	2021-07-09	1'000	LU2358476476	OROSEIC LX	0.80%	20.00%
I-D CHF	Institutional - Distribution (dividend)	CHF	2021-07-09	1'000	LU2358476559	OROSEID LX	0.80%	20.00%

*Other share classes are available upon request*

## Copernicus Wealth Management

Swiss centre of excellence for innovation-oriented Asset Management, Wealth Management, Risk Management and family office financial services Founded in December 2016, Copernicus is an independent financial group with offices in Lugano and Zurich. The Group is majority-owned by its founding partners. In 2017, Copernicus Wealth Management obtained its licence for the Collective Investment Schemes Act (CISA) by the Swiss Financial Market Supervisory Authority (FINMA). The offer of Copernicus includes Asset Management, Risk Management, Family Office, Investment Advisory and Wealth Planning services. Copernicus Wealth Management acts independently of banks or other financial entities with complete freedom of choice of financial products and services. The Group currently comprises of Copernicus Wealth Management, Finpartner Financial Services and Thalia Capital Advisors.



## Disclaimer

This is an advertising document. The state of the origin of Centrica – Orchestra Swiss Equity Fund (the "Fund") is Luxembourg. This document may only be provided to qualified investors in Switzerland within the meaning of art. 10 para. 3 and 3ter CISA and to professional investors in Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zürich, whilst the paying agent is Credit Suisse (Switzerland) Ltd, Paradeplatz 8, CH-8001 Zurich. The basic documents of the Fund as well as the annual and, if applicable, semi-annual report may be obtained free of charge from the representative. In respect of the units offered in or from Switzerland, the place of performance is the registered office of the representative and the place of jurisdiction is the registered office of the representative or the registered office or place of residence of the investor. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming shares. Past performance may not be reliable guide to future performance. The current document is intended for informational purposes only and shall not be used as an offer to buy and/or sell shares. Before the subscription you should read the prospectus. Unless otherwise stated, opinions, calculations and estimates included in this report do not constitute the judgment of Copernicus Wealth Management SA ("Copernicus") and are subject to change without notice. Information in this report is obtained from various secondary sources that are believed to be reliable; However, Copernicus cannot guarantee its accuracy and such information may be incomplete or condensed. Certain information is presented as background on market historical characteristics. Performance analysis assumes an investment at the beginning of the period and reinvestment of the proceeds from such investment over the entire period. Investment performance provided does reflect management fees, performance fees and other expenses. Historical market characteristics may not be indicative of future market characteristics. This report is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase any securities in any jurisdiction in which such an offer or solicitation is not authorized. Further, this report is not to be construed as investment advice. No securities are offered in the United States or to US persons and securities are not registered in the United States under the 1933 act. Investing in financial products involves risks, including in particular those associated to market fluctuations as well as the inherent risk of every product type. Investments may also be affected by changes to the rules and regulations governing exchange controls or taxation, including withholding tax, or by changes to economic and monetary policies. No guarantee can be given that the indicated objectives will be achieved and that investors will recover the amount of their initial investment. Past performance is not an indicator for future results or performance. Financial products are exposed to various risks, depending on its complexity, structure and investment policies. The possible investment must be independently assessed on the basis of the prospectus of the financial instrument and the suitability of the financial instrument with the specific characteristics of each investor. Neither this report nor any part hereof may be reproduced or distributed without prior written authorization of Copernicus.